

South Surrey 1688 – 152nd Street Suite 306 South Surrey, BC Canada V4A 4N2

> Phone 604 538 1611 Fax 604 538 1633

October 14, 2011

To: British Columbia Securities Commission

Dear Sirs,

We refer to the final, long form Non-offering Prospectus of Pacific Therapeutics Ltd. (the "Company") dated October 14, 2011.

We consent to being named in and to the use, through incorporation by reference in the Prospectus, of our report to the shareholders of the Company dated May 30, 2011, (except as to note 13, which is dated August 23, 2011) and our report to the shareholders of the Company, dated January 29, 2010, on the following financial statements:

- Balance sheets as at December 31, 2010, 2009 and 2008;
- Statements of operations and deficit and cash flows for the years ended December 31, 2010 2009 and 2008.

The prospectus also incorporates by reference the following unaudited interim financial statements of the Company:

- Balance sheets as at June 30, 2011 and June 30, 2010;
- Statements of loss and deficit and cash flows for the three-month and six-month periods ended June 30, 2011 and June 30, 2010.

We have not performed an audit or review of the financial statements of the Company for the three-month and six-month periods ended June 30, 2010. We have, however, performed a review of the unaudited interim financial statements of the Company as at June 30, 2011 and for the three-month and six-month periods ended June 30, 2011. We performed our review in accordance with Canadian generally accepted standards for a review of interim financial statements by an entity's auditor. Such an interim review consists principally of applying analytical procedures to financial data, and making enquiries of, and having discussions with, persons responsible for financial and accounting matters. An interim review is substantially less in scope than an audit, whose objective is the expression of an opinion regarding the financial statements. An interim review does not provide assurance that we would become aware of any or all-significant matters that might be identified in an audit.

Based on our review, we are not aware of any material modification that needs to be made for these interim financial statements to be in accordance with Canadian generally accepted accounting principles.

We have read the Prospectus and all information incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements.

This letter is provided solely for the purpose of assisting the securities regulatory authorities to which it is addressed in discharging their responsibilities and should not be used for any other purpose. Any use that a third party makes of this letter, or any reliance or decisions made based on it, are the responsibilities of such third parties. We accept no responsibility for loss or damages, if any, suffered by a third party as a result of decisions made or actions taken based on this letter.

Yours very truly,

UHY LAMB Advisors Inc.

Surrey, British Columbia October 14, 2011

CHARTERED ACCOUNTANTS

